MCID: MYL005
MIFTS: 72

Myelofibrosis malady

Genetic diseases, Rare diseases, Cancer diseases, Bone diseases, Immune diseases categories

Summaries for Myelofibrosis

About this section
Sources:
9Disease Ontology, 22Genetics Home Reference, 44NIH Rare Diseases, 66Wikipedia, 48OMIM, 34MalaCards
See all sources

Fully expand this MalaCard

Download this MalaCard
NIH Rare Diseases:44 Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by fibrous (scar) tissue. scarring of the bone marrow causes anemia, which can lead to fatigue and weakness, as well as pooling of the blood in abnormal sites like the liver and spleen, causing these organs to swell. although myelofibrosis can occur at any age, it typically develops after the age of 50. in most cases, myelofibrosis gets progressively worse. treatment is aimed at relieving signs and symptoms and may include medications, blood transfusions, chemotherapy, radiation therapy and surgery.    last updated: 8/17/2011

MalaCards: Myelofibrosis, also known as primary myelofibrosis, is related to polycythemia and polycythemia vera. An important gene associated with Myelofibrosis is JAK2 (Janus kinase 2), and among its related pathways are Integrin alphaIIb beta3 signaling and Paxillin-dependent events mediated by a4b1. The drug busulfan and the compounds megapoietin and pp 100 have been mentioned in the context of this disorder. Affiliated tissues include the bone marrow which results_in bone marrow being replaced by fibrous (scar) tissue, bone and bone marrow, and related mouse phenotypes are tumorigenesis and embryogenesis.

Disease Ontology:9 A myeloma that is located in the bone marrow which results in bone marrow being replaced by fibrous (scar) tissue.

Genetics Home Reference:22 Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.

Wikipedia:66 Myelofibrosis, also known as osteomyelofibrosis, is a disorder of the bone marrow. It is currently... more...

Description from OMIM:48 254450

Aliases & Classifications for Myelofibrosis

About this section
Sources:
9Disease Ontology, 44NIH Rare Diseases, 23GTR, 11DISEASES, 46Novoseek, 32LifeMap Discovery™, 63UMLS, 22Genetics Home Reference, 36MeSH, 48OMIM, 59SNOMED-CT, 41NCIt, 28ICD9CM
See all sources

Classifications:



Aliases & Descriptions:

myelofibrosis 9 44 23 11 46 32 63
primary myelofibrosis 9 44 22 46 63
agnogenic myeloid metaplasia 9 44 22 46
myeloid metaplasia 44 22 46 63
idiopathic myelofibrosis 44 22 46
chronic idiopathic myelofibrosis 9 22
megakaryocytic myelosclerosis 9 63
myelofibrosis with myeloid metaplasia 22
idiopathic bone marrow fibrosis 9
bone marrow fibrosis 9
myelosclerosis, nos 9
aleukemic myelosis 9
myelosclerosis 9


External Ids:

Disease Ontology9 DOID:4971
MeSH36 D055728
OMIM48 254450
NCIt41 C2862
ICD9CM28 238.76

Related Diseases for Myelofibrosis

About this section
Sources:
18GeneCards, 19GeneDecks
See all sources

Diseases in the Myelofibrosis family:

Familial Myelofibrosis

Diseases related to Myelofibrosis via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 206)
idRelated DiseaseScoreTop Affiliating Genes
1polycythemia31.0CD177, IL3, JAK2, EPO, MPL, THPO
2polycythemia vera30.8CD177, KIT, IL3, JAK2, EPO, MPL
3leukemia30.8THPO, MPL, EPO, JAK2, IL3, KIT
4splenomegaly30.7THPO, MPL, EPO, JAK2
5leukemoid reaction30.6IL3, GATA1
6myeloid leukemia30.4THPO, MPL, JAK2, IL3, KIT, GATA1
7megakaryocytic leukemia30.4THPO, IL3, GATA1
8myelodysplastic syndromes30.3THPO, MPL, CD177, GATA1, KIT, IL3
9chronic myelomonocytic leukemia30.3MPL, JAK2, KIT
10sarcoma30.3KIT, JAK2, THPO
11thrombocytosis30.3THPO, MPL, EPO, JAK2, IL3, CD177
12pancytopenia30.3THPO, MPL, EPO, IL3
13thrombocytopenia30.3THPO, MPL, EPO, IL3, GATA1
14hypereosinophilic syndrome30.3IL3, KIT
15chronic myeloproliferative disease30.2JAK2, MPL, THPO
16beta thalassemia30.2EPO, GATA1
17myeloma30.2EPO, JAK2, IL3, FGF2
18hypersplenism30.1THPO
19myelofibrosis, somatic30.1SH2B3, JAK2
20systemic mastocytosis30.1JAK2, KIT
21myeloproliferative disorder30.0FGF2, CD177, GATA1, KIT, IL3, JAK2
22refractory anemia29.9KIT, IL3, JAK2, EPO, MPL, THPO
23chronic myeloid leukemia29.8MPL, THPO, EPO, JAK2, IL3, CD177
24aplastic anemia29.7THPO, MPL, EPO, IL3, GATA1
25hemorrhagic thrombocythemia29.7KIT, IL3, JAK2, EPO, MPL, THPO
26deficiency anemia29.6THPO, MPL, EPO, JAK2, IL3, GATA1
27erythrocytosis29.6MPL, EPO, JAK2, IL3, CD177
28neutropenia29.6THPO, MPL, EPO, IL3, CD177
29acute lymphocytic leukemia29.6THPO, MPL, JAK2, IL3, KIT, GATA1
30acute leukemia29.6THPO, MPL, EPO, JAK2, IL3, KIT
31essential thrombocythemia10.8
32acute panmyelosis with myelofibrosis10.6
33osteosclerosis10.4
34acute myeloid leukemia10.4
35hypertension10.3
36nocardiosis10.3
37aspergillosis10.3
38hepatic vascular disease10.3
39vascular disease10.3
40hematopoietic stem cell transplantation10.3
41endotheliitis10.2
42pyridoxine deficiency10.2
43rickets10.2
44hepatitis10.2
45myelofibrosis with myeloid metaplasia, somatic10.2
46lymphoblastic leukemia10.1
47multiple myeloma10.1
48familial myelofibrosis10.1
49gray platelet syndrome10.1
50thrombocythemia 110.1THPO

Graphical network of the top 20 diseases related to Myelofibrosis:



Diseases related to myelofibrosis

Symptoms for Myelofibrosis

About this section
Sources:
48OMIM
See all sources


Clinical features from OMIM:

254450

Drugs & Therapeutics for Myelofibrosis

About this section
Sources:
6CenterWatch, 43NIH Clinical Center, 7ClinicalTrials, 32LifeMap Discovery™, 63UMLS, 42NDF-RT
See all sources

Approved drugs:

Search CenterWatch for Myelofibrosis

Drug clinical trials:

Search ClinicalTrials for Myelofibrosis

Search NIH Clinical Center for Myelofibrosis

Search CenterWatch for Myelofibrosis

Inferred drug relations via UMLS63/NDF-RT42:

Cell-based therapeutics:


LifeMap Discovery
The database of embryonic development, stem cell research and regenerative medicine
Read about Myelofibrosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myelofibrosis:
Peripheral blood-derived hematopoietic stem cells for treatment of myelofibrosis
Embryonic/Adult Cultured Cells Related to Myelofibrosis:
Peripheral blood-derived hematopoietic stem cells (family)

Genetic Tests for Myelofibrosis

About this section
Sources:
23GTR
See all sources

Genetic tests related to Myelofibrosis:

id Genetic test Affiliating Genes
1 Myelofibrosis23

Anatomical Context for Myelofibrosis

About this section
Sources:
34MalaCards, 15FMA
See all sources

MalaCards organs/tissues related to Myelofibrosis:

34
Bone, Bone marrow, Myeloid, Spleen, Liver, T cells, Endothelial, Monocytes, Nk cells, B cells, Prostate, Lung, Whole blood, Colon, Breast, Lymph node, Brain, Spinal cord, Testes, Kidney, Ovary

FMA organs/tissues related to Myelofibrosis:

15
The bone marrow which results_in bone marrow being replaced by fibrous (scar) tissue

Animal Models for Myelofibrosis or affiliated genes

About this section
Sources:
38MGI
See all sources

MGI Mouse Phenotypes related to Myelofibrosis:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.6FGF2, KIT, IL3, JAK2
2MP:00053808.6MPL, EPO, JAK2, KIT, GATA1
3MP:00028738.1EPO, JAK2, FKBP5, KIT, GATA1
4MP:00053877.6THPO, SH2B3, MPL, JAK2, IL3, KIT
5MP:00053847.3SH2B3, MPL, EPO, JAK2, IL3, KIT
6MP:00053767.2MPL, EPO, JAK2, FKBP5, IL3, KIT
7MP:00107687.1MPL, EPO, JAK2, FKBP5, IL3, KIT
8MP:00053977.0FGF2, THPO, SH2B3, MPL, EPO, JAK2

Publications for Myelofibrosis

About this section
Sources:
53PubMed
See all sources

Articles related to Myelofibrosis:

(show top 50)    (show all 783)
idTitleAuthorsYear
1
SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. (23558523)
2013
2
Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis. (24176039)
2013
3
Reversible bone marrow aplasia induced by pegylated interferon-I+-2a therapy in a patient with primary myelofibrosis. (24067929)
2013
4
Chromosome 5q deletion is extremely rare in patients with myelofibrosis. (23391517)
2013
5
Myelofibrosis in Philadelphia chromosome-negative myeloproliferative neoplasms is associated with aberrant karyotypes. (23571153)
2013
6
Lymphodepletion chemotherapy followed by donor leukocytes for post-transplantation relapse of myelofibrosis after previous donor leukocyte infusion failure. (23110685)
2013
7
Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. (23349007)
2013
8
JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis. (23555782)
2013
9
The relationship of the active and latent forms of TGF-I^1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis. (22200991)
2012
10
Myelofibrosis: a cause of increased transfusion requirement in a child with I^-thalassemia intermedia. (22009011)
2012
11
Clinical, histopathologic, and genetic features of pediatric primary myelofibrosis--an entity different from adults. (22389089)
2012
12
Guideline for the diagnosis and management of myelofibrosis. (22651893)
2012
13
JAK2 V617F, MPL W515L and JAK2 Exon 12 Mutations in Chinese Patients with Primary Myelofibrosis. (23359764)
2012
14
GR SNP helps transform myelofibrosis. (23065009)
2012
15
Ruxolitinib for myelofibrosis therapy: current context, pros and cons. (22285996)
2012
16
Ruxolitinib: in the treatment of myelofibrosis. (23061804)
2012
17
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial. (21480207)
2011
18
Ruxolitinib for the treatment of myelofibrosis. (22146225)
2011
19
Bone marrow fibrosis in myeloproliferative neoplasms-associated myelofibrosis: deconstructing a myth? (21296418)
2011
20
The surgical palliative treatment of myelofibrosis. Personal experience. (21682106)
2011
21
Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. (19786111)
2010
22
Pyoderma gangrenosum associated with chronic idiopathic myelofibrosis after coronary artery bypass graft surgery. (19846444)
2010
23
Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets. (20113333)
2010
24
Thrombosis in primary myelofibrosis: incidence and risk factors. (19965680)
2010
25
JAK inhibition in myelofibrosis. (21158663)
2010
26
Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy. (19052692)
2009
27
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. (19720904)
2009
28
Massive eyelid thickening in pachydermoperiostosis with myelofibrosis. (19617796)
2009
29
JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. (19616600)
2009
30
The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. (18266209)
2008
31
Plasma cell leukemia with myelofibrosis. (19039200)
2008
32
Myelofibrosis in a child with EBV-associated hemophagocytic lymphohistiocytosis. (18454467)
2008
33
A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis. (17361221)
2007
34
Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. (17317589)
2007
35
No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis. (17162218)
2006
36
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. (16834459)
2006
37
Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia. (15755503)
2005
38
A patient with TP53 germline mutation developed Bowen's disease and myelodysplastic syndrome with myelofibrosis after chemotherapy against ovarian cancer. (15942101)
2005
39
Acute panmyelosis with myelofibrosis: clinical, immunophenotypic and cytogenetic study of twelve cases. (15223649)
2004
40
Systemic lupus erythematosus presenting with pancytopenia due to bone marrow myelofibrosis in a 22-year-old male. (16163223)
2004
41
Impaired NK cell differentiation of blood-derived CD34+ progenitors from patients with myeloid metaplasia with myelofibrosis. (12706407)
2003
42
SU6668 in idiopathic myelofibrosis--a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis. (12888313)
2003
43
Lack of alteration in GATA-1 expression in CD34+ hematopoietic progenitors from patients with idiopathic myelofibrosis. (12788793)
2003
44
The therapy of myelofibrosis: targeting pathogenesis. (12430941)
2002
45
Esophageal variceal ligation for esophageal variceal hemorrhage in a patient with portal and primary pulmonary hypertension complicating myelofibrosis. (11330433)
2001
46
Erythroleukemia following erythropoietin therapy, extramedullary hematopoiesis, and splenectomy in a patient with myelofibrosis and myeloid metaplasia. (11391725)
2001
47
Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. (10550553)
1999
48
Laparoscopically assisted splenectomy following preoperative splenic artery embolization using contour emboli for myelofibrosis with massive splenomegaly. (10804000)
1999
49
PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis. (10497847)
1999
50
Myelofibrosis secondary to renal osteodystrophy. (8730443)
1996

Variations for Myelofibrosis

About this section

Expression for genes affiliated with Myelofibrosis

About this section
Sources:
2BioGPS, 16Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Myelofibrosis

Search GEO for disease gene expression data for Myelofibrosis.

Pathways for genes affiliated with Myelofibrosis

About this section
Sources:
51PathCards, 56Reactome, 39NCBI BioSystems Database, 5Cell Signaling Technology, 61Thomson Reuters, 55R&D Systems, 54QIAGEN, 31KEGG
See all sources

Pathways related to Myelofibrosis according to GeneCards/GeneDecks:

(show all 32)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.9MPL, THPO
2
Show member pathways
Paxillin-independent events mediated by a4b1 and a4b739
a4b1 and a4b7 Integrin signaling39
9.8JAK2, EPO
39.8JAK2, GATA1
4
Show member pathways
Development Thrombopoetin signaling via JAK STAT pathway61
9.6JAK2, MPL, THPO
5
Show member pathways
IL-9 Signaling Pathway39
Development Thrombopoietin regulated cell processes61
IL-7 Signaling Pathway39
Immune response IL 9 signaling pathway61
9.6THPO, MPL, JAK2
69.5FGF2, KIT
7
Show member pathways
EPO Receptor Signaling39
EPO signaling pathway39
9.4JAK2, EPO, SH2B3
8
Show member pathways
9.4FGF2, JAK2, MPL
99.4GATA1, JAK2, SH2B3
10
Show member pathways
Development EDNRB signaling61
Development ACM2 and ACM4 activation of ERK61
Cell adhesion Integrin inside out signaling61
Development G Proteins mediated regulation MARK ERK signaling61
Signal transduction IP3 signaling61
Development Angiotensin signaling via PYK261
Development EPO induced MAPK pathway61
9.3EPO, JAK2, KIT
119.2JAK2, KIT, FGF2
129.2GATA1, IL3, JAK2
13
Show member pathways
9.1FGF2, IL3, THPO
149.0GATA1, KIT, IL3
15
Show member pathways
Type III interferon signaling39
8.9MPL, EPO, JAK2, IL3
16
Show member pathways
Signaling events mediated by Stem cell factor receptor (c-Kit)39
8.9SH2B3, EPO, JAK2, KIT
17
Show member pathways
8.8SH2B3, JAK2, KIT, FGF2
188.7KIT, IL3, EPO, THPO
19
Show member pathways
8.6FGF2, KIT, IL3, THPO
20
Show member pathways
8.6FGF2, KIT, IL3, THPO
21
Show member pathways
8.6THPO, IL3, KIT, FGF2
22
Show member pathways
8.6THPO, IL3, KIT, FGF2
23
Show member pathways
8.6THPO, IL3, KIT, FGF2
24
Show member pathways
8.4MPL, EPO, JAK2, IL3, KIT
25
Show member pathways
8.3FGF2, KIT, IL3, JAK2, THPO
26
Show member pathways
8.3THPO, JAK2, IL3, KIT, FGF2
27
Show member pathways
8.3KIT, IL3, JAK2, THPO, FGF2
28
Show member pathways
8.3THPO, JAK2, IL3, KIT, FGF2
29
Show member pathways
8.3THPO, JAK2, IL3, KIT, FGF2
308.2EPO, JAK2, IL3, KIT, FGF2
31
Show member pathways
8.0THPO, SH2B3, MPL, JAK2, GATA1, CD177
32
Show member pathways
7.6FGF2, THPO, MPL, EPO, JAK2, IL3

Compounds for genes affiliated with Myelofibrosis

About this section
Sources:
46Novoseek, 25HMDB, 12DrugBank, 30IUPHAR, 52PharmGKB, 62Tocris Bioscience, 3BitterDB
See all sources

Compounds related to Myelofibrosis according to GeneCards/GeneDecks:

(show top 50)    (show all 81)
idCompoundScoreTop Affiliating Genes
1megapoietin4610.2THPO, MPL
2pp 1004610.1JAK2, EPO
3beta-tyrosine4610.0JAK2, KIT
4thromboxane46 2510.8THPO, MPL, GATA1
5pegfilgrastim46 1210.8EPO, IL3
6su6668469.8KIT, FGF2
7il 11469.7IL3, EPO
8anagrelide46 1210.7JAK2, EPO, MPL, THPO
9pixy321469.6THPO, EPO, IL3
10mafosfamide469.6THPO, IL3
11amifostine46 1210.6IL3, EPO, THPO
12filgrastim46 1210.6IL3, EPO, THPO
13gm-csf46 3010.6IL3, EPO, THPO
14aclarubicin469.5GATA1, IL3
15carboplatin46 52 1211.4THPO, EPO, IL3
16doxycycline46 1210.4FGF2, IL3, EPO
17iron46 2510.3THPO, MPL, EPO, GATA1
185-aza-2deoxycytidine469.3THPO, EPO, JAK2, IL3
19gf 109203x46 6210.1FGF2, JAK2, THPO
20ascorbic acid46 2510.1EPO, JAK2, IL3, FGF2
215fluorouracil469.1KIT, IL3, MPL, THPO
22genistein46 30 62 3 25 1214.0THPO, JAK2, IL3, FGF2
23phosphotyrosine469.0KIT, IL3, JAK2, SH2B3
24butyrate468.9THPO, EPO, JAK2, IL3, GATA1
25agar468.9FGF2, IL3, JAK2, MPL, THPO
26vincristine46 52 1210.9FGF2, KIT, IL3
27paclitaxel46 52 1210.9THPO, IL3, KIT, FGF2
28ly294002468.8THPO, EPO, JAK2, IL3, FGF2
29imatinib46 52 1210.8THPO, EPO, JAK2, IL3, KIT
30steroid468.8THPO, JAK2, FKBP5, KIT, GATA1
31alanine468.8FGF2, IL3, JAK2, MPL, THPO
32cytarabine46 52 1210.7THPO, EPO, IL3, KIT, GATA1
33pd 98,059468.7THPO, JAK2, IL3, KIT, FGF2
34methylcellulose468.7THPO, EPO, IL3, KIT, FGF2
35cyclosporin a46 30 6210.6EPO, JAK2, FKBP5, IL3, FGF2
36dexamethasone46 52 30 1211.6FGF2, IL3, FKBP5, JAK2, THPO
37lactate468.6THPO, EPO, IL3, KIT
38cysteine468.5KIT, IL3, JAK2, MPL, THPO
39gp 130468.5THPO, MPL, EPO, JAK2, IL3, KIT
40hydroxyurea46 52 1210.5GATA1, KIT, IL3, JAK2, EPO, THPO
41thymidine46 259.4THPO, EPO, JAK2, IL3, KIT, FGF2
42actinomycin d468.3THPO, JAK2, IL3, KIT, GATA1, FGF2
43vegf468.3THPO, MPL, EPO, JAK2, KIT, GATA1
44rapamycin468.3THPO, EPO, JAK2, FKBP5, IL3, KIT
45estrogen468.3THPO, JAK2, IL3, KIT, GATA1, FGF2
46retinoic acid46 259.3THPO, JAK2, IL3, KIT, GATA1, FGF2
47serine468.2MPL, JAK2, IL3, KIT, GATA1, FGF2
48cycloheximide468.1JAK2, FKBP5, IL3, KIT, GATA1, FGF2
49phosphatidylinositol467.7THPO, SH2B3, MPL, EPO, JAK2, IL3
50tyrosine466.8THPO, SH2B3, MPL, EPO, JAK2, IL3

GO Terms for genes affiliated with Myelofibrosis

About this section
Sources:
17Gene Ontology
See all sources

Cellular components related to Myelofibrosis according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1extracellular spaceGO:0056158.2FGF2, KIT, IL3, EPO, THPO

Biological processes related to Myelofibrosis according to GeneCards/GeneDecks:

(show all 16)
idNameGO IDScoreTop Affiliating Genes
1response to axon injuryGO:0486789.9EPO, FGF2
2positive regulation of tyrosine phosphorylation of Stat3 proteinGO:0425179.8KIT, JAK2
3cellular response to thyroid hormone stimulusGO:0970679.8GATA1, KIT
4positive regulation of phospholipase C activityGO:0108639.7FGF2, KIT
5positive regulation of phosphatidylinositol 3-kinase activityGO:0435529.6FGF2, KIT
6positive regulation of DNA replicationGO:0457409.6EPO, IL3
7positive regulation of phosphatidylinositol 3-kinase signalingGO:0140689.6JAK2, KIT
8erythrocyte differentiationGO:0302189.6GATA1, KIT, JAK2
9activation of MAPKK activityGO:0001869.4FGF2, JAK2
10positive regulation of peptidyl-tyrosine phosphorylationGO:0507319.4JAK2, IL3, GATA1
11negative regulation of cell proliferationGO:0082859.4FGF2, GATA1, JAK2
12positive regulation of tyrosine phosphorylation of Stat5 proteinGO:0425239.0KIT, IL3, JAK2, EPO
13signal transductionGO:0071658.9FGF2, KIT, JAK2, EPO
14embryonic hemopoiesisGO:0351628.8SH2B3, IL3, KIT, GATA1
15positive regulation of cell proliferationGO:0082848.5EPO, JAK2, IL3, KIT, FGF2
16blood coagulationGO:0075968.2THPO, SH2B3, MPL, JAK2, GATA1, CD177

Molecular functions related to Myelofibrosis according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1cytokine activityGO:0051259.1FGF2, IL3, THPO
2growth factor activityGO:0080838.8FGF2, IL3, THPO

Products for genes affiliated with Myelofibrosis

About this section
  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Myelofibrosis

About this section
4CDC
14ExPASy
15FMA
23GTR
24HGMD
25HMDB
26ICD10
27ICD10 via Orphanet
28ICD9CM
30IUPHAR
31KEGG
36MeSH
37MESH via Orphanet
38MGI
41NCIt
42NDF-RT
45NINDS
46Novoseek
48OMIM
49OMIM via Orphanet
53PubMed
54QIAGEN
60SNOMED-CT via Orphanet
63UMLS
64UMLS via Orphanet